The negative momentum and pessimism around this name amazes me. At some point value matters. Even if you think hep C is on the fast track to the bottom, there will still be patients to treat and revenues to earn. You can eliminate half the profits (which is pretty crazy) and GILD would trade at 14x, less than a market multiple for a company that has traditionally generated tremendous returns for investors. Probably need positive data or a deal to get the momentum to turn around though. Good news in NASH or RA/Crohn's would get investors excited again.
News 
Market Data 
Discover 
